PD-1/PD-L1抑制剂与多药联合治疗三阴性乳腺癌的研究进展

Advances in research on triple-negative breast cancer in combination with PD-1/PD-L1 inhibitor and multidrug therapy

因缺乏明确的分子靶点,三阴性乳腺癌(TNBC)与其他乳腺癌亚型相比是较难治疗以及预后较差的乳腺癌亚型。程序性死亡受体-配体1(PD-L1)在TNBC中表达明显增加,其免疫逃逸机制使其更适用于免疫检查点阻断治疗。然而,临床试验中TNBC对抗PD-L1或抗程序性死亡受体1(PD-1)治疗的反应率并不令人满意,客观反应率只有10%~20%,可能与TNBC具有免疫沉默效应有关,因此免疫检查点阻断剂与其他药物的联合策略可能会增加TNBC的临床获益率。本文综述TNBC中PD-1/PD-L1抑制剂联合其他药物的研究进展,为临床医生设计多药联合策略提供依据。

Because of the lack of clear molecular targets,triple-negative breast cancer(TNBC)is a more difficult to treat and a poorer prognosis of breast cancer subtypes compared to other breast cancer subtypes.Programmed death-ligand 1(PD-L1)is significantly increased in TNBC,and its immune escape mechanism makes it more suitable for immunological checkpoint blockade.However,the response rate of TNBC against PD-L1 or anti-programmed death 1(PD-1)treatment in clinical trials is not satisfactory,and the objective response rate is only 10%~20%,which may be related to the immune silencing effect of TNBC.Therefore,the combined strategy of immunological checkpoint blockers and other drugs may increase the clinical benefit rate of TNBC.This article reviews the research progress of PD-1/PD-L1 inhibitors in combination with other drugs in TNBC,and provides a basis for clinicians to design multi-drug joint strategies.